Dianeal + Physioneal + Extraneal + Nutrineal
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ESRD
Conditions
ESRD, Diabetes
Trial Timeline
Apr 1, 2008 → Jul 1, 2011
NCT ID
NCT00567398About Dianeal + Physioneal + Extraneal + Nutrineal
Dianeal + Physioneal + Extraneal + Nutrineal is a phase 3 stage product being developed by Baxter for ESRD. The current trial status is completed. This product is registered under clinical trial identifier NCT00567398. Target conditions include ESRD, Diabetes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00567398 | Phase 3 | Completed |
Competing Products
17 competing products in ESRD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat | AstraZeneca | Phase 3 | 77 |
| Doravirine | Merck | Approved | 85 |
| MK-2060 + Placebo | Merck | Phase 1 | 33 |
| Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI | Novartis | Approved | 85 |
| Mycophenolic Acid (Myfortic) | Novartis | Approved | 85 |
| Avacopan | Amgen | Phase 1 | 32 |
| [¹⁴C]Etelcalcetide | Amgen | Phase 1 | 32 |
| apixaban | Bristol Myers Squibb | Phase 2 | 51 |
| ISIS 416858 + Placebo | Bayer | Phase 2 | 49 |
| ISIS 416858 + Placebo | Bayer | Phase 2 | 49 |
| 10 GE Xenokidney | United Therapeutics | Phase 1/2 | 38 |
| GGTA1 KO Thymokidney | United Therapeutics | Phase 1/2 | 38 |
| Physioneal + Dianeal + Extraneal + Nutrineal | Baxter | Approved | 82 |
| Dianeal + Dianeal, Extraneal, Nutrineal | Baxter | Phase 3 | 74 |
| Acellular Tissue Engineered Vessel (ATEV) | Humacyte | Phase 3 | 69 |
| Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate | Rockwell Medical | Phase 2 | 44 |
| soluble ferric pyrophosphate (SFP) | Rockwell Medical | Pre-clinical | 15 |